lithium-chloride and 6-methyl-2-(phenylethynyl)pyridine

lithium-chloride has been researched along with 6-methyl-2-(phenylethynyl)pyridine* in 4 studies

Other Studies

4 other study(ies) available for lithium-chloride and 6-methyl-2-(phenylethynyl)pyridine

ArticleYear
Drosophila PQBP1 regulates learning acquisition at projection neurons in aversive olfactory conditioning.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2010, Oct-20, Volume: 30, Issue:42

    Polyglutamine tract-binding protein-1 (PQBP1) is involved in the transcription-splicing coupling, and its mutations cause a group of human mental retardation syndromes. We generated a fly model in which the Drosophila homolog of PQBP1 (dPQBP1) is repressed by insertion of piggyBac. In classical odor conditioning, learning acquisition was significantly impaired in homozygous piggyBac-inserted flies, whereas the following memory retention was completely normal. Mushroom bodies (MBs) and antennal lobes were morphologically normal in dPQBP1-mutant flies. Projection neurons (PNs) were not reduced in number and their fiber connections were not changed, whereas gene expressions including NMDA receptor subunit 1 (NR1) were decreased in PNs. Targeted double-stranded RNA-mediated silencing of dPQBP1 in PNs, but not in MBs, similarly disrupted learning acquisition. NR1 overexpression in PNs rescued the learning disturbance of dPQBP1 mutants. HDAC (histone deacetylase) inhibitors, SAHA (suberoylanilide hydroxamic acid) and PBA (phenylbutyrate), that upregulated NR1 partially rescued the learning disturbance. Collectively, these findings identify dPQBP1 as a novel gene regulating learning acquisition at PNs.

    Topics: Animals; Avoidance Learning; Blotting, Northern; Conditioning, Operant; Dendrites; Drosophila; Histone Deacetylase Inhibitors; Immunohistochemistry; Lithium Chloride; Mushroom Bodies; Mutation; Neurons; Oligopeptides; Psychomotor Performance; Pyridines; Receptors, Metabotropic Glutamate; Receptors, N-Methyl-D-Aspartate; Reverse Transcriptase Polymerase Chain Reaction; RNA; Smell

2010
Elevated glycogen synthase kinase-3 activity in Fragile X mice: key metabolic regulator with evidence for treatment potential.
    Neuropharmacology, 2009, Volume: 56, Issue:2

    Significant advances have been made in understanding the underlying defects of and developing potential treatments for Fragile X syndrome (FXS), the most common heritable mental retardation. It has been shown that neuronal metabotropic glutamate receptor 5 (mGluR5)-mediated signaling is affected in FX animal models, with consequent alterations in activity-dependent protein translation and synaptic spine functionality. We demonstrate here that a central metabolic regulatory enzyme, glycogen synthase kinase-3 (GSK3) is present in a form indicating elevated activity in several regions of the FX mouse brain. Furthermore, we show that selective GSK3 inhibitors, as well as lithium, are able to revert mutant phenotypes of the FX mouse. Lithium, in particular, remained effective with chronic administration, although its effects were reversible even when given from birth. The combination of an mGluR5 antagonist and GSK3 inhibitors was not additive. Instead, it was discovered that mGluR5 signaling and GSK3 activation in the FX mouse are coordinately elevated, with inhibition of mGluR5 leading to inhibition of GSK3. These findings raise the possibility that GSK3 is a fundamental and central component of FXS pathology, with a substantial treatment potential.

    Topics: Acoustic Stimulation; Analysis of Variance; Animals; Antimanic Agents; Brain; Citrates; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Routes; Enzyme Inhibitors; Excitatory Amino Acid Antagonists; Exploratory Behavior; Fragile X Mental Retardation Protein; Gene Expression Regulation; Glycogen Synthase Kinase 3; Indoles; Lithium Chloride; Male; Maleimides; Mice; Mice, Knockout; Pyridines; Seizures; Serine; Thiazoles; Urea

2009
MPEP, a selective metabotropic glutamate receptor 5 antagonist, attenuates conditioned taste aversion in rats.
    Behavioural brain research, 2003, May-15, Volume: 141, Issue:2

    Metabotropic glutamate receptors (mGluRs) have been implicated in several types of cognitive and associative learning. Although recent evidence indicates an influence of mGluRs in conditioned taste aversion (CTA), the subtype-specific involvement of mGluRs in this learning paradigm remained to be determined. The aim of this study was to examine the role of Group I mGluR subtypes in CTA using a selective mGluR5 antagonist (2-methyl-6-(phenylethynyl)-pyridine, MPEP) and a selective mGluR1 antagonist (1-aminoindan-1,5-dicarboxylic acid, AIDA). Male, water-deprived, Sprague-Dawley rats were injected i.p. with 6 or 12 mg/kg MPEP or saline. Twenty-five minutes later, all rats received 15-min access to a 0.1% saccharin solution (Sac) immediately followed by an injection of 0.15M LiCl at 1.33% body weight. The animals were tested with 15-min access to Sac on each of four test days. MPEP-treated animals consumed more Sac on the test trials than saline-treated rats. In another experiment, controlled access to Sac was used by infusing the solution on the conditioning trial. Consistent with the above results, MPEP attenuated the degree of CTA. Similar experiments using the mGluR1 antagonist AIDA, have found no effect on CTA learning. These results suggest that the two subtypes of Group I mGluRs are differentially involved in taste aversion learning.

    Topics: Animals; Avoidance Learning; Excitatory Amino Acid Antagonists; Indans; Lithium Chloride; Male; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Saccharin; Taste

2003
2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist.
    Neuropharmacology, 1999, Volume: 38, Issue:10

    In the present paper we describe 2-methyl-6-(phenylethynyl)-pyridine (MPEP) as a potent, selective and systemically active antagonist for the metabotropic glutamate receptor subtype 5 (mGlu5). At the human mGlu5a receptor expressed in recombinant cells, MPEP completely inhibited quisqualate-stimulated phosphoinositide (PI) hydrolysis with an IC50 value of 36 nM while having no agonist or antagonist activities at cells expressing the human mGlu1b receptor at concentrations up to 30 microM. When tested at group II and III receptors, MPEP did not show agonist or antagonist activity at 100 microM on human mGlu2, -3, -4a, -7b, and -8a receptors nor at 10 microM on the human mGlu6 receptor. Electrophysiological recordings in Xenopus laevis oocytes demonstrated no significant effect at 100 microM on human NMDA (NMDA1A/2A), rat AMPA (Glu3-(flop)) and human kainate (Glu6-(IYQ)) receptor subtypes nor at 10 microM on the human NMDA1A/2B receptor. In rat neonatal brain slices, MPEP inhibited DHPG-stimulated PI hydrolysis with a potency and selectivity similar to that observed on human mGlu receptors. Furthermore, in extracellular recordings in the CA1 area of the hippocampus in anesthetized rats, the microiontophoretic application of DHPG induced neuronal firing that was blocked when MPEP was administered by iontophoretic or intravenous routes. Excitations induced by microiontophoretic application of AMPA were not affected.

    Topics: Animals; Animals, Newborn; Brain; Cell Line; Cyclic AMP; Excitatory Amino Acid Antagonists; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Lithium Chloride; Male; Methoxyhydroxyphenylglycol; Oocytes; Phosphatidylinositols; Pyridines; Quisqualic Acid; Radioligand Assay; Rats; Rats, Inbred Strains; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Recombinant Proteins; Sulfur Radioisotopes; Transfection; Xenopus laevis

1999